



ADVANCING SCIENCE.*
ENHANCING VISION.

Oxurion NV to Present at the 2019 BIO CEO & Investor Conference

Leuven, Belgium, 4 February 2019 - [Oxurion NV](#) (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that Patrik De Haes, M.D., chief executive officer, will present a company overview and clinical update at the 2019 [BIO CEO & Investor Conference](#). The presentation will take place at 11:15 a.m. EST on Tuesday, Feb. 12, 2019 in the Herald/Soho room at the New York Marriott Marquis.

Oxurion's management team will also hold one-on-one meetings with institutional investors and analysts Feb. 11-14 in New York.

Patrik De Haes, MD, CEO of Oxurion NV, commented: *"It is a particularly pivotal time at Oxurion given the progress of our 4 clinical programs, each slated to read out in the second half of 2019. We look forward to providing a company update at the BIO CEO & Investor Conference as we continue to advance our pipeline of disease-modifying therapies in the clinic and remain confident in the potential of each therapy to preserve vision in patients with diabetic eye disease."*

END

For further information please contact:

Oxurion NV Wouter Piepers, Global Head of Corp Coms & Investor relations +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@oxurion.com	
EU - Citigate Dewe Rogerson David Dible/ Sylvie Berrebi Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com	US - LifeSci Public Relations Alison Chen +1 646-876-4932 achen@lifescipublicrelations.com

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company focused on transforming treatments to preserve vision in patients with diseases affecting the back of the eye. The company is currently developing a competitive pipeline of disease-modifying drug candidates for diabetic eye disease, a leading cause of blindness of people of working age worldwide.

Oxurion's most advanced drug candidate is THR-317, a PIGF inhibitor for the treatment of diabetic macular edema (DME), which is currently in a Phase 2 study in combination with Lucentis®. THR-317 is also being evaluated in a Phase 2 study for the treatment of Idiopathic

Macular Telangiectasia Type 1 (MacTel 1), a rare retinal disease that affects the macula and can lead to vision loss.

Oxurion has two further pipeline candidates, THR-149, a plasma kallikrein inhibitor being developed for the treatment of DME; and THR-687, a pan-RGD integrin antagonist in development for the treatment of diabetic retinopathy and DME. Both THR-149 and THR-687 are in Phase 1 clinical studies.

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

More information is available at www.oxurion.com.